Document is current
Any future updates will be listed below
-
Authors
Chesney, Jason A https://orcid.org/0000-0003-0217-8278
Puzanov, Igor https://orcid.org/0000-0002-9803-3497
Collichio, Frances A
Singh, Parminder
Milhem, Mohammed M
Glaspy, John
Hamid, Omid
Ross, Merrick
Friedlander, Philip
Garbe, Claus
Logan, Theodore
Hauschild, Axel
Lebbé, Celeste
Joshi, Harshada
Snyder, Wendy
Mehnert, Janice M
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01740297 at ClinicalTrials.govnct01740297 at ClinicalTrials.govDocuments that mention this clinical trial
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
https://doi.org/10.1136/jitc-2022-006270
433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial
https://doi.org/10.1136/jitc-2020-sitc2020.0433
Documents that mention this clinical trial
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
https://doi.org/10.1136/jitc-2022-006270
433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial
https://doi.org/10.1136/jitc-2020-sitc2020.0433
-
Funding
Funding for this research was provided by:
Amgen Inc (N/A)
- License Information
